Related Experiment Videos
Harmonization of bioavailability and bioequivalence requirements
1Bureau of Drug Research, Health Protection Branch, Ottawa, Ontario, Canada.
European Journal of Drug Metabolism and Pharmacokinetics
|January 1, 1991
Summary
Drug product bioavailability (BA) and bioequivalence (BE) regulations differ globally. This analysis compares European Community (EC) and North American standards, highlighting areas for potential international consensus in drug approval processes.
Area of Science:
- Pharmaceutical Sciences
- Regulatory Affairs
- Drug Development
Background:
- Global pharmaceutical regulations for drug product bioavailability (BA) and bioequivalence (BE) have evolved based on legal precedents.
- While scientific principles are shared, specific standards for BA/BE requirements often vary between different jurisdictions.
- Harmonizing these standards is crucial for efficient global drug development and market access.
Purpose of the Study:
- To compare and contrast the bioavailability (BA) and bioequivalence (BE) requirements between the European Community (EC) and North American regulatory bodies.
- To identify specific areas where regulatory consensus on BA/BE standards is achievable.
- To highlight persistent challenges in achieving global harmonization of BA/BE guidelines.
Main Methods:
- Comparative analysis of existing regulatory guidelines and legal precedents for bioavailability (BA) and bioequivalence (BE) in the EC and North America.
- Examination of scientific principles underpinning BA/BE assessments across different regions.
- Identification of commonalities and divergences in specific BA/BE standards and acceptance criteria.
Main Results:
- Significant similarities exist in the underlying scientific principles for BA/BE assessment.
- Differences are noted in specific standards, such as in vivo study designs and acceptance criteria for bioequivalence (BE).
- Areas for potential consensus include general approaches to BA/BE, while specific statistical methods and in vitro dissolution criteria present challenges.
Conclusions:
- While a common scientific foundation exists, achieving full international consensus on BA/BE requirements necessitates addressing specific regulatory and methodological differences.
- Targeted discussions on statistical analysis and dissolution testing could facilitate greater harmonization.
- Understanding regional nuances in BA/BE regulations is essential for pharmaceutical companies navigating global drug product approvals.